Mark Charles Nahmias, DPM | |
5906 E 31st St, Suite 1, Tulsa, OK 74135-5110 | |
(918) 749-9996 | |
(918) 622-9998 |
Full Name | Mark Charles Nahmias |
---|---|
Gender | Male |
Speciality | |
Experience | Years |
Location | 5906 E 31st St, Tulsa, Oklahoma |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1285716142 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
213E00000X | Podiatrist | 166 (Oklahoma) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mark Charles Nahmias, DPM 5906 E 31st St, Suite 1, Tulsa, OK 74135-5110 Ph: (918) 749-9996 | Mark Charles Nahmias, DPM 5906 E 31st St, Suite 1, Tulsa, OK 74135-5110 Ph: (918) 749-9996 |
News Archive
Researchers at the University of East Anglia are launching a new project to develop methods which could one-day decrease the use of rats and mice in pharmaceutical testing.
Living through a tragic event might make us more inclined to live for the moment, but not always in a good way. Research is looking into the psychological after-effects among children who survived the 2011 Great East Japan Earthquake, and a recent study may have made a connection: the children may forgo greater long-term reward for short-term pleasure.
Chronix Biomedical today reported a summary of data supporting the utility of its serum DNA blood tests for the early and accurate detection of breast cancer and prostate cancer. The unique testing algorithms developed by Chronix detected and correctly identified DNA fragments in the blood from dying (apoptotic) cancer cells with 92% sensitivity and 100% specificity in both prostate cancer and breast cancer.
Amarillo Biosciences, Inc. (OTCBB: AMAR) today announced that a Phase 2 study of orally administered interferon-alpha for the prevention of influenza and winter colds has reached the midway point. The study in Perth, Australia achieved full target enrollment of 200 subjects and 98% of the subjects remain on study drug. Subjects in the study are receiving a lozenge containing interferon-alpha or a matching placebo once a day for 16 weeks.
› Verified 4 days ago
Dr. Abdurrahman Kabani, D.P.M. Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 6160 S Yale Ave, Tulsa, OK 74136 Phone: 918-499-4780 Fax: 918-499-4781 | |
Jeff Robert Finkenstaedt, D.P.M. Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 3540 East 31st, Suite 2, Tulsa, OK 74135 Phone: 918-747-8997 Fax: 918-744-8011 | |
Maureen Lee Crotty, DPM Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 3627 S Harvard Ave, Tulsa, OK 74135 Phone: 918-494-2902 Fax: 918-494-2905 | |
Dr. Robert Hayes Lee, D.P.M. Podiatrist Medicare: May Accept Medicare Assignments Practice Location: 3315 E 47th Pl, Suite 102, Tulsa, OK 74135 Phone: 918-749-4484 Fax: 918-749-2350 | |
David Alan Francis, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 3627 S Harvard Ave, Tulsa, OK 74135 Phone: 918-747-4855 Fax: 918-747-4866 | |
Timothy B. Maclin Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 4415 S Harvard Ave, Suite 101, Tulsa, OK 74135 Phone: 918-749-3228 Fax: 918-747-2759 | |
Mark C. Nahmias, Dpm, Pllc Podiatrist Medicare: Medicare Enrolled Practice Location: 5906 E 31st St, Suite 1, Tulsa, OK 74135 Phone: 918-749-9996 Fax: 918-622-9998 |